These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 30603741)

  • 21. Toxicities associated with adoptive cellular therapies.
    Hansen DK; Dam M; Faramand RG
    Best Pract Res Clin Haematol; 2021 Sep; 34(3):101287. PubMed ID: 34625233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.
    Xia AL; Wang XC; Lu YJ; Lu XJ; Sun B
    Oncotarget; 2017 Oct; 8(52):90521-90531. PubMed ID: 29163850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New development in CAR-T cell therapy.
    Wang Z; Wu Z; Liu Y; Han W
    J Hematol Oncol; 2017 Feb; 10(1):53. PubMed ID: 28222796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield.
    Jo Y; Ali LA; Shim JA; Lee BH; Hong C
    Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32731404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
    Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
    J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
    Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
    Front Immunol; 2018; 9():2740. PubMed ID: 30559740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
    Neelapu SS; Tummala S; Kebriaei P; Wierda W; Gutierrez C; Locke FL; Komanduri KV; Lin Y; Jain N; Daver N; Westin J; Gulbis AM; Loghin ME; de Groot JF; Adkins S; Davis SE; Rezvani K; Hwu P; Shpall EJ
    Nat Rev Clin Oncol; 2018 Jan; 15(1):47-62. PubMed ID: 28925994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis.
    Lei W; Xie M; Jiang Q; Xu N; Li P; Liang A; Young KH; Qian W
    Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current development of chimeric antigen receptor T-cell therapy.
    Wang J; Hu Y; Huang H
    Stem Cell Investig; 2018; 5():44. PubMed ID: 30701179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
    Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
    BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current Progress in CAR-T Cell Therapy for Solid Tumors.
    Ma S; Li X; Wang X; Cheng L; Li Z; Zhang C; Ye Z; Qian Q
    Int J Biol Sci; 2019; 15(12):2548-2560. PubMed ID: 31754328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytokine release syndrome complicated with rhabdomyolysis after chimeric antigen receptor T-cell therapy: A case report.
    Zhang L; Chen W; Wang XM; Zhang SQ
    World J Clin Cases; 2022 Sep; 10(26):9398-9403. PubMed ID: 36159401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
    Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric Antigen Receptor T Cells in Hematologic Malignancies.
    Shank BR; Do B; Sevin A; Chen SE; Neelapu SS; Horowitz SB
    Pharmacotherapy; 2017 Mar; 37(3):334-345. PubMed ID: 28079265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment.
    Titov A; Valiullina A; Zmievskaya E; Zaikova E; Petukhov A; Miftakhova R; Bulatov E; Rizvanov A
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31947775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
    DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
    Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
    J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
    Liu Y; Chen X; Han W; Zhang Y
    Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.